References
- DeVaultKRTalleyNJInsights into the future of gastric acid suppressionNat Rev Gastroenterol Hepatol2009652453219713987
- VakilyMZhangWWuJAtkinsonSNMulfordDPharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trialsCurr Med Res Opin20092562763819232037
- MetzDCVakilyMDixitTMulfordDReview article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapyAliment Pharmacol Ther20092992893719298580
- Dexilant® (dexlansoprazole) delayed release capsules [package insert]Deerfield, ILTakeda Pharmaceuticals America Inc2011
- Nexium® (esomeprazole magnesium) delayed-release capsules [package insert]Wilmington, DEAstraZeneca Pharmaceuticals LP2011
- LeeRDVakilyMMulfordDWuJAtkinsonSNClinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor – evidence for dosing flexibilityAliment Pharmacol Ther20092982483319243357
- MinerPJrKatzPOChenYSostekMGastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover studyAm J Gastroenterol2003982616262014687806
- MinerPBJrTutuianRCastellDOLiuSSostekMBIntragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: An open-label crossover study in healthy adult volunteersClin Ther20062872573316861094
- WarringtonSBaisleyKDunnKBoyceMMorocuttiAEffects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjectsEur J Clin Pharmacol20066268569116850327
- MorelliGChenHRossiterGRegeBLuYAn open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteersAliment Pharmacol Ther20113384585421272047
- ThoringMHedenströmHErikssonLSRapid effect of lansoprazole on intragastric pH: A crossover comparison with omeprazoleScand J Gastroenterol19993434134510365892
- HunfeldNGTouwDJMathotRAA comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphismAliment Pharmacol Ther20103115015919785625
- BladhNBlychertEJohanssonKA new esomeprazole packet (sachet) formulation for suspension: In vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteersClin Ther20072964064917617287
- JunghardOHassan-AlinMHasselgrenGThe effect of area under the plasma concentration vs time curve on the maximum plasma concentration of esomeprazole on intragastric pHEur J Clin Pharmacol20025845345812389067
- Hassan-AlinMAnderssonTBredbergERöhssKPharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjectsEur J Clin Pharmacol20005666567011214773
- BellNJVBurgetDHowdenCWWilkinsonJHuntRHAppropriate acid suppression for the management of gastro-oesophageal reflux diseaseDigestion199251Suppl 159671397746
- ArmstrongDReview article: Gastric pH – the most relevant predictor of benefit in reflux disease?Aliment Pharmacol Ther200420Suppl 5192615456460
- KatzPOGinsbergGGHoylePESostekMBMonyakJTSilbergDGRelationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitisAliment Pharmacol Ther20072561762817305763